While chest pain is not a common side effect listed in FDA prescribing information, patients may experience chest discomfort through various mechanisms including gastrointestinal effects, reflux, or unrelated cardiac conditions
Retatrutide has not received marketing authorisation from the MHRA or EMA and is only available within regulated clinical trials
In order to limit GLP-1 costs and prioritize the cohorts most at risk, payers should develop a risk stratification rubric to segment and prioritize patients for GLP-1 weight loss coverage in cases where it is medically necessary and/or where cost of care can be lowered the most
Designed for gentle longevity support Formulated to support metabolic health, graceful aging, mood, and focus
doi: 10.1016/S2213-8587(21)00203-5
About the author Cassie McGrath Cassie McGrath is a reporter at Healthcare Brew, where she focuses on the inner-workings and business of hospitals, unions, policy, and how AI is impacting the industry.
